Literature DB >> 15201192

Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood.

Willem F M Arts1, Oebele F Brouwer, A C Boudewijn Peters, Hans Stroink, Els A J Peeters, Paul I M Schmitz, Cees A van Donselaar, Ada T Geerts.   

Abstract

Knowing the prognosis of epilepsy will undoubtedly influence the treatment strategy. This study aimed to define the prospects of newly diagnosed childhood epilepsy, assess the dynamics of its course, identify relevant variables and develop models to assess the individual prognosis. Four hundred and fifty-three children with newly diagnosed epilepsy were followed for 5 years. Terminal remission at 5 years (TR5) was compared with terminal remission at 2 years (TR2) and with the longest remission during follow-up. Variables defined at intake and at 6 months of follow-up were analysed for their prognostic relevance. In multivariate analyses, combinations of variables were tested to develop reliable models for the calculation of the individual prognosis. Data on treatment, course during follow-up and epilepsy syndromes were also studied. Three hundred and forty-five children (76%) had a TR5 >1 year, 290 (64%) >2 years and 65 (14%) had not had any seizure during the entire follow-up. Out of 108 children (24%) with TR5 <1 year, 27 were actually intractable at 5 years. Medication was started in 388 children (86%). In 227 of these (59%), anti-epileptic drugs (AEDs) could be withdrawn. A TR5 >1 year was attained by 46% on one AED, on the second AED by 19%, and by 9% on all additional AED regimes. Almost 60% of the children treated with a second or additional AED regime had a TR5 >1 year. Variables predicting the outcome at intake were aetiology, history of febrile seizures and age. For intake and 6-month variables combined, sex, aetiology, postictal signs, history of febrile seizures and TR at 6 months were significant. The model derived from intake variables only predicted TR5 <1 year correctly in 36% and TR5 >1 year in 85% (sensitivity 0.65, specificity 0.64). The corresponding values for the model derived from intake and 6-month variables were 43 and 88% (sensitivity 0.69, specificity 0.71). The course of the epilepsy was constantly favourable in 51%, steadily poor in 17%, improving in 25% and deteriorating in 6%. Intractability was in part only a temporary phenomenon. The outcome at 5 years in this cohort of children with newly diagnosed epilepsy was favourable in 76%; 64% were off medication at that time. Almost a third of the children had a fluctuating course; improvement was clearly more common than deterioration. After failure of the first AED, treatment can still be successful. Models predicting the outcome have fewer misclassifications when predicting a long terminal remission than when predicting continuing seizures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201192     DOI: 10.1093/brain/awh200

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  30 in total

1.  Honing in on risk factors for prolonged remission off medication by reducing heterogeneity.

Authors:  Dale C Hesdorffer
Journal:  Epilepsy Curr       Date:  2012-05       Impact factor: 7.500

2.  Refractory epilepsy: one size does not fit all.

Authors:  Jacqueline A French
Journal:  Epilepsy Curr       Date:  2006 Nov-Dec       Impact factor: 7.500

3.  The natural history of seizures and neuropsychiatric symptoms in childhood epilepsy with centrotemporal spikes (CECTS).

Authors:  Erin E Ross; Sally M Stoyell; Mark A Kramer; Anne T Berg; Catherine J Chu
Journal:  Epilepsy Behav       Date:  2019-10-20       Impact factor: 2.937

4.  Complete remission of childhood-onset epilepsy: stability and prediction over two decades.

Authors:  Anne T Berg; Karen Rychlik; Susan R Levy; Francine M Testa
Journal:  Brain       Date:  2014-10-22       Impact factor: 13.501

5.  Can neural network able to estimate the prognosis of epilepsy patients according to risk factors?

Authors:  Kezban Aslan; Hacer Bozdemir; Cenk Sahin; S Noyan Ogulata
Journal:  J Med Syst       Date:  2009-03-28       Impact factor: 4.460

Review 6.  Management of the patient with medically refractory epilepsy.

Authors:  Tiziana Granata; Nicola Marchi; Erin Carlton; Chaitali Ghosh; Jorge Gonzalez-Martinez; Andreas V Alexopoulos; Damir Janigro
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

7.  Frequency, prognosis and surgical treatment of structural abnormalities seen with magnetic resonance imaging in childhood epilepsy.

Authors:  Anne T Berg; Gary W Mathern; Richard A Bronen; Robert K Fulbright; Francis DiMario; Francine M Testa; Susan R Levy
Journal:  Brain       Date:  2009-07-28       Impact factor: 13.501

8.  Antiepileptic drug utilization in children from 1997-2005--a study from the Netherlands.

Authors:  N W van de Vrie-Hoekstra; T W de Vries; P B van den Berg; O F Brouwer; L T W de Jong-van den Berg
Journal:  Eur J Clin Pharmacol       Date:  2008-07-10       Impact factor: 2.953

9.  Standard antiepileptic drugs fail to block epileptiform activity in rat organotypic hippocampal slice cultures.

Authors:  K Albus; A Wahab; U Heinemann
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

Review 10.  Identification of pharmacoresistant epilepsy.

Authors:  Anne T Berg
Journal:  Neurol Clin       Date:  2009-11       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.